Phase i -topic 431 - drug delivery by endoesophageal lavage (EEL) to treat esophageal cancer
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00018
- Awardee
-
Isola Therapeutics Inc. UEI M3QDM72NME75
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $455,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $455,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 17 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Minneapolis, MN 55410, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $55,000 | |
| Original award | $400,000 |
About this award
The U.S. National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase I contract to Isola Therapeutics Inc., a for-profit small business, for the project "Drug Delivery by Endoesophageal Lavage (EEL) to Treat Esophageal Cancer". The $455,000 fixed-price contract has a period of performance through March 14, 2025. This award was made under the NCI's SBIR program, which aims to stimulate technological innovation, strengthen the role of small businesses in federal research and development, and increase commercialization of innovations derived from federal research. The original pre-solicitation notice listed this topic among over 100 potential research areas spanning infectious diseases, cancer, aging, and public health for small businesses to propose.
Quick answers
Who was awarded contract 75N91022C00018?
75N91022C00018 was awarded to Isola Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is contract 75N91022C00018 worth?
The government has obligated $455,000 on 75N91022C00018.
Was contract 75N91022C00018 competed?
The extent of competition for 75N91022C00018 was full and open competition after exclusion of sources. The government received 17 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award